Add a bookmark to get started

14 July 20233 minute read

DLA Piper wins big at the LMG Life Sciences Awards

DLA Piper was presented with five awards and was shortlisted for a further four at the 2023 LMG Life Sciences Annual Awards ceremony, in London, on 13 July.

Now in its 11th year, the annual LMG Life Sciences Awards are presented to the in-house counsel, law firms, individual private practitioners, and corporations behind the most innovative and challenging legal work across the life sciences industries from across the world.

On the night, DLA Piper won:

  • Impact Deal of the Year: GE HealthCare Technologies spinoff
  • Impact Deal of the Year: Philip Morris acquisition of Swedish Match
  • EMEA Antitrust & Competition Firm of the Year
  • Corporate Rising Star – Dylan Kennett
  • Regulatory Rising Star – Marion Abecassis

DLA Piper was also shortlisted in a further four categories including:

  • M&A Team of the Year
  • UK Team of the Year
  • Germany Team of the Year
  • Eastern Europe Team of the Year.

Marco de Morpurgo, IPT Partner and International Head of Life Sciences at DLA Piper, commented: “To win one award in recognition of your successes is a source of pride. But, to come home with five is a ringing endorsement of the quality of work we do, the depth of knowledge and expertise that is held within our global team. It is also fantastic to see those individuals awarded for their particular contributions. I am extremely proud that our dedication to delivering outstanding results for our clients has been recognised in such a way.”

Tom Heylen, DLA Piper Corporate Partner and Head of UK Clients and Sectors, said: “The firm has worked on some outstanding Life Sciences transactions over the past 12-months, so it is really encouraging to receive these awards. Both the Philip Morris and GE deals relied on us working seamlessly across specific areas and numerous geographies which is a testament to the strength of our teams and the firm’s global footprint.”

Working across more than 50 jurisdictions, DLA Piper’s Life Sciences sector combines legal and regulatory experience with deep knowledge of the sector, including pharmaceuticals, medical devices, biotech, health-tech, clinical research services, and the latest therapeutic innovations.